Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hasbro, Inc. (HAS) vs Pfizer Inc (PFE) Price & Performance

Hasbro, Inc.Trade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Hasbro, Inc. vs Pfizer Inc — how do they compare? Hasbro, Inc. trades at $97.28 (market cap $13.33B), while Pfizer Inc trades at $26.6 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 11.6× Hasbro, Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.36%). Which is the better fit depends on your goals.

HASPFE
Market Cap
$13.33B$154.18B
Sector
Consumer CyclicalHealth
52-Week High
$105.88$28.56
52-Week Low
$70.95$23.60
Enterprise Value
$15.52B$205.67B
Dividend Yield
2.96%6.36%
Volume
29,869,932

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hasbro, Inc.

Hasbro (HAS) trades at $93.52, up 2.0% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust revenue growth driven by Magic: The Gathering and digital gaming, though net income turned negative in 2025. Analyst consensus is a Buy with a $104.90 price target, supported by institutional accumulation and positive media coverage on franchise strength.

Outlook remains positive with 2026 revenue projected at $5.0B and net income of $794M, but risks include high debt levels, margin pressures from tariffs, and cybersecurity concerns. The stock offers a 2.93% dividend yield, with upside potential if growth sustains, yet volatility may persist amid cost headwinds.

Pfizer Inc

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Hasbro, Inc.

Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.

Read more on HAS

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE